Yahoo
NasdaqGM - Nasdaq Real Time Price USD

NewAmsterdam Pharma Company N.V. (NAMS)

20.06 -0.70 (-3.37%)
At close: October 30 at 4:00:00 PM EDT
20.00 -0.06 (-0.30%)
After hours: October 30 at 6:23:29 PM EDT
Trade NAMS on Coinbase
Chart Range Bar
Loading chart for NAMS
  • Previous Close 20.76
  • Open 20.60
  • Bid 19.66 x 200
  • Ask 33.17 x 200
  • Day's Range 19.78 - 20.94
  • 52 Week Range 19.13 - 42.21
  • Volume 1,139,894
  • Avg. Volume 1,470,018
  • Market Cap (intraday) 2.398B
  • Beta (5Y Monthly) 0.10
  • PE Ratio (TTM) --
  • EPS (TTM) -2.16
  • Earnings Date (est.) Nov 4, 2026
  • Forward Dividend & Yield -- (0.00%)
  • 1y Target Est 49.79
  • Zacks Rating Neutral

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.

www.newamsterdampharma.com

100

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Recent News

View More

Performance Overview

Trailing total returns as of 10/30/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

NAMS
42.82%
S&P 500 (^GSPC)
10.73%

1-Year Return

NAMS
48.19%
S&P 500 (^GSPC)
11.11%

3-Year Return

NAMS
179.78%
S&P 500 (^GSPC)
81.91%

5-Year Return

NAMS
104.49%
S&P 500 (^GSPC)
64.59%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q2 FY26
Revenue 3.21M
Earnings -55.55M
Profit Margin -1,732.91%

Q3

FY25

Q4

FY25

Q1

FY26

Q2

FY26

-60M
-40M
-20M
0
-200000.0%
-150000.0%
-100000.0%
-50000.0%

Analyst Insights

View More

Analyst Price Targets

37.91
49.79 Average
20.06 Current
59.12 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 10/5/2026
Analyst RBC Capital
Rating Action Maintains
Rating Outperform
Price Action Lowers
Price Target 50 -> 42

Statistics

View More

Valuation Measures

Annual
As of 10/30/2026
  • Market Cap

    2.40B

  • Enterprise Value

    1.76B

  • Trailing P/E

    --

  • Forward P/E

    105.58

  • PEG Ratio (current)

    --

  • Price/Sales (ttm)

    340.93

  • Price/Book (mrq)

    3.74

  • Enterprise Value/Revenue

    247.74

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -20.10%

  • Return on Equity (ttm)

    -36.81%

  • Revenue (ttm)

    7.12M

  • Net Income Avi to Common (ttm)

    -259.5M

  • Diluted EPS (ttm)

    -2.16

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    633.85M

  • Total Debt/Equity (mrq)

    0.01%

  • Levered Free Cash Flow (ttm)

    -45.36M

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights

Fair Value

20.06 Current

Dividend Score

0 Low
Sector Avg.
100 High

Hiring Score

0 Low
Sector Avg.
100 High

Insider Sentiment Score

0 Low
Sector Avg.
100 High

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: